|
3-Pyrrolidineacetic acid, α,α′,α′′-[nitrilotris(methylene-3,1-phenylenemethylene)]tris-, (αS,α′S,α′′S,3R,3′R,3′′R)- Suppliers list
|
| Company Name: |
Zibo Hangyu Biotechnology Development Co., Ltd |
| Tel: |
+86-0533-2185556 +8615965530500 |
| Email: |
nickzhang@hangyubiotech.com |
| Products Intro: |
Product Name:3-Pyrrolidineacetic acid, α,α′,α′′-[nitrilotris(methylene-3,1-phenylenemethylene)]tris-, (αS,α′S,α′′S,3R,3′R,3′′R)-
CAS:2565656-70-2
Purity:99%
|
|
|
|
|
3-Pyrrolidineacetic acid, α,α′,α′′-[nitrilotris(methylene-3,1-phenylenemethylene)]tris-, (αS,α′S,α′′S,3R,3′R,3′′R)- manufacturers
- Muvalaplin
-
- $148.00 / 1mg
-
2026-01-29
- CAS:2565656-70-2
- Min. Order:
- Purity: 99.59%
- Supply Ability: 10g
- Muvalaplin
-
- $0.00 / 100gram
-
2025-08-22
- CAS:2565656-70-2
- Min. Order: 10gram
- Purity: 99% min
- Supply Ability: 20 TONS
|
| | 3-Pyrrolidineacetic acid, α,α′,α′′-[nitrilotris(methylene-3,1-phenylenemethylene)]tris-, (αS,α′S,α′′S,3R,3′R,3′′R)- Basic information |
| Product Name: | 3-Pyrrolidineacetic acid, α,α′,α′′-[nitrilotris(methylene-3,1-phenylenemethylene)]tris-, (αS,α′S,α′′S,3R,3′R,3′′R)- | | Synonyms: | Muvalaplin;LY3473329;(2S,2'S,2''S)-3,3',3''-((Nitrilotris(methylene))tris(benzene-3,1-diyl))tris(2-((R)-pyrrolidin-3-yl)propanoic acid);3-Pyrrolidineacetic acid, α,α′,α′′-[nitrilotris(methylene-3,1-phenylenemethylene)]tris-, (αS,α′S,α′′S,3R,3′R,3′′R)-;(2S)-3-[3-[[bis[[3-[(2S)-2-carboxy-2-[(3R)-pyrrolidin-3-yl]ethyl]phenyl]methyl]amino]methyl]phenyl]-2-[(3R)-pyrrolidin-3-yl]propanoic acid | | CAS: | 2565656-70-2 | | MF: | C42H54N4O6 | | MW: | 710.9 | | EINECS: | | | Product Categories: | | | Mol File: | 2565656-70-2.mol | ![3-Pyrrolidineacetic acid, α,α′,α′′-[nitrilotris(methylene-3,1-phenylenemethylene)]tris-, (αS,α′S,α′′S,3R,3′R,3′′R)- Structure](CAS/20240320/GIF/2565656-70-2.gif) |
| | 3-Pyrrolidineacetic acid, α,α′,α′′-[nitrilotris(methylene-3,1-phenylenemethylene)]tris-, (αS,α′S,α′′S,3R,3′R,3′′R)- Chemical Properties |
| Boiling point | 863.9±60.0 °C(Predicted) | | density | 1.234±0.06 g/cm3(Predicted) | | solubility | PBS (pH 7.2): Slightly Soluble: 0.1-1 mg/ml | | pka | 3.79±0.10(Predicted) | | form | Solid | | color | Off-white to light yellow | | InChIKey | BRLGERLDHZRETI-BGBFCPIGSA-N | | SMILES | [C@H]([C@]1([H])CNCC1)(C(=O)O)CC1C=CC=C(C=1)CN(CC1C=CC=C(C=1)C[C@@H]([C@]1([H])CNCC1)C(=O)O)CC1C=CC=C(C=1)C[C@@H]([C@]1([H])CNCC1)C(=O)O |
| | 3-Pyrrolidineacetic acid, α,α′,α′′-[nitrilotris(methylene-3,1-phenylenemethylene)]tris-, (αS,α′S,α′′S,3R,3′R,3′′R)- Usage And Synthesis |
| Uses | Muvalaplin (LY3473329) is an orally active, selective small molecule inhibitor of lipoprotein (a) (Lp (a)) that disrupts the initial non-covalent interaction between apo(a) and apoB100, preventing the disulphide bond and Lp(a)
formation. Muvalaplin reduces the levels of Lp (a) in transgenic mice and in cynomolgus monkeys[1][2][3][4][5]. | | in vivo | Muvalaplin (1-30 mg/kg, p.o., daily for 5 days) reduces the levels of Lp(a) in the Lp (a) transgenic mouse model[3].
Muvalaplin (1-100 mg/kg, p.o., daily for 15 days) reduces the levels of Lp (a) levels in cynomolgus monkeys[3].
| Animal Model: | Lp (a) transgenic mouse model[3] | | Dosage: | 1-30 mg/kg | | Administration: | p.o., daily for 5 days | | Result: | Reduced the levels of Lp(a) with an absolute ED50 of 3mg/kg. |
| Animal Model: | Cynomolgus monkeys[3] | | Dosage: | 1-100 mg/kg | | Administration: | p.o., daily for 15 days | | Result: | Reduced median Lp(a) levels in a dose-dependent manner by up to 71%. |
| | References | [1] Bhatia HS, et al. Lipoprotein(a): Evidence for Role as a Causal Risk Factor in Cardiovascular Disease and Emerging Therapies. J Clin Med. 2022 Oct 13;11(20):6040. DOI:10.3390/jcm11206040
[2] Nicholls SJ, et al. Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial. JAMA. 2023 Sep 19;330(11):1042-1053. DOI:10.1001/jama.2023.16503
[3] Diaz N, et al. Discovery of potent small-molecule inhibitors of lipoprotein(a) formation. Nature. 2024 May;629(8013):945-950. DOI:10.1038/s41586-024-07387-z
[4] Hooper AJ, et al. Potential of muvalaplin as a lipoprotein(a) inhibitor. Expert Opin Investig Drugs. 2024 Jan;33(1):5-7. DOI:10.1080/13543784.2024.2302592
[5] Norata GD, et al. Oral strategies to target proprotein convertase subtilisin/kexin type 9 and lipoprotein(a): the new frontier of lipid lowering. Eur Heart J. 2023 Dec 21;44(48):5018-5020. DOI:10.1093/eurheartj/ehad682 |
| | 3-Pyrrolidineacetic acid, α,α′,α′′-[nitrilotris(methylene-3,1-phenylenemethylene)]tris-, (αS,α′S,α′′S,3R,3′R,3′′R)- Preparation Products And Raw materials |
|